Meridian Bioscience: Q2 Earnings Insights
Meridian Bioscience NASDAQ:VIVO reported its Q2 earnings results on
Here's what investors need to know about the announcement.
Earnings
Meridian Bioscience beat estimated earnings by 40.43%, reporting an EPS of
Revenue was up
Past Earnings Performance
Last quarter the company beat on EPS by
Here's a look at Meridian Bioscience's past performance:
Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
---|---|---|---|---|
EPS Estimate | 0.25 | 0.20 | 0.31 | 0.48 |
EPS Actual | 0.35 | 0.23 | 0.22 | 0.56 |
Revenue Estimate | 70.29M | 68.40M | 77.22M | 84.48M |
Revenue Actual | 88.34M | 76.20M | 63.51M | 85.26M |
To track all earnings releases for Meridian Bioscience visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.